

**Replacement Abstract**

This invention relates to methods for replicating human cytomegalovirus (HCMV) genetically engineered for optimized antigenicity. The invention further relates to the use of such viral and sub-viral particles for the production of vaccines against HCMV-mediated diseases and infections.